About
Technology
Issues
FAQ
Links
Official Page
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.